Oramed Pharmaceuticals (ORMP) Competitors $2.32 -0.09 (-3.73%) Closing price 04:00 PM EasternExtended Trading$2.34 +0.02 (+0.86%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ORMP vs. BNTC, IMAB, UPXI, RCKT, ABEO, CGC, FDMT, ALT, ALDX, and FHTXShould you be buying Oramed Pharmaceuticals stock or one of its competitors? The main competitors of Oramed Pharmaceuticals include Benitec Biopharma (BNTC), I-Mab (IMAB), Upexi (UPXI), Rocket Pharmaceuticals (RCKT), Abeona Therapeutics (ABEO), Canopy Growth (CGC), 4D Molecular Therapeutics (FDMT), Altimmune (ALT), Aldeyra Therapeutics (ALDX), and Foghorn Therapeutics (FHTX). These companies are all part of the "pharmaceutical products" industry. Oramed Pharmaceuticals vs. Its Competitors Benitec Biopharma I-Mab Upexi Rocket Pharmaceuticals Abeona Therapeutics Canopy Growth 4D Molecular Therapeutics Altimmune Aldeyra Therapeutics Foghorn Therapeutics Oramed Pharmaceuticals (NASDAQ:ORMP) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability. Does the media refer more to ORMP or BNTC? In the previous week, Benitec Biopharma had 1 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 2 mentions for Benitec Biopharma and 1 mentions for Oramed Pharmaceuticals. Benitec Biopharma's average media sentiment score of 1.72 beat Oramed Pharmaceuticals' score of 0.95 indicating that Benitec Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Oramed Pharmaceuticals Positive Benitec Biopharma Very Positive Is ORMP or BNTC more profitable? Oramed Pharmaceuticals' return on equity of -19.37% beat Benitec Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Oramed PharmaceuticalsN/A -19.37% -18.28% Benitec Biopharma N/A -38.26%-35.71% Which has preferable earnings and valuation, ORMP or BNTC? Oramed Pharmaceuticals has higher revenue and earnings than Benitec Biopharma. Benitec Biopharma is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOramed Pharmaceuticals$1.34M70.99-$19.06M-$0.35-6.63Benitec Biopharma$80K4,495.31-$21.75M-$1.51-9.07 Which has more volatility and risk, ORMP or BNTC? Oramed Pharmaceuticals has a beta of 1.69, meaning that its share price is 69% more volatile than the S&P 500. Comparatively, Benitec Biopharma has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Do analysts rate ORMP or BNTC? Benitec Biopharma has a consensus target price of $26.00, suggesting a potential upside of 89.78%. Given Benitec Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Benitec Biopharma is more favorable than Oramed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Benitec Biopharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Do institutionals and insiders believe in ORMP or BNTC? 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are held by institutional investors. 17.8% of Oramed Pharmaceuticals shares are held by company insiders. Comparatively, 1.3% of Benitec Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryOramed Pharmaceuticals and Benitec Biopharma tied by winning 8 of the 16 factors compared between the two stocks. Get Oramed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORMP vs. The Competition Export to ExcelMetricOramed PharmaceuticalsMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$95.12M$10.46B$5.75B$10.28BDividend YieldN/A1.87%5.72%4.60%P/E Ratio-6.6320.5674.9926.41Price / Sales70.9930.44456.1088.49Price / CashN/A25.0025.8129.91Price / Book0.643.4313.256.28Net Income-$19.06M$210.63M$3.29B$270.38M7 Day Performance0.87%-0.88%0.46%2.69%1 Month Performance11.54%1.64%4.59%5.98%1 Year Performance-6.83%-11.61%73.41%25.93% Oramed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORMPOramed Pharmaceuticals0.6134 of 5 stars$2.32-3.7%N/A-3.2%$95.12M$1.34M-6.6310BNTCBenitec Biopharma1.6653 of 5 stars$13.84-0.5%$26.00+87.9%+69.9%$365.14M$80K-9.1720Positive NewsIMABI-Mab2.6342 of 5 stars$4.27-2.5%$7.00+63.9%+285.8%$357.67M$3.89M0.00380Gap DownUPXIUpexi3.0437 of 5 stars$5.66-6.3%$15.50+173.9%+73.7%$355.69M$26M0.00130Short Interest ↓RCKTRocket Pharmaceuticals4.7933 of 5 stars$3.26-0.6%$16.73+413.3%-83.9%$353.92MN/A-1.30240Positive NewsShort Interest ↑ABEOAbeona Therapeutics4.1136 of 5 stars$6.70-2.8%$19.50+191.0%+15.2%$353.31M$3.50M9.5790Positive NewsCGCCanopy Growth1.1009 of 5 stars$1.35-7.5%N/A-71.4%$350.18M$225.65M-0.453,150Positive NewsFDMT4D Molecular Therapeutics2.6612 of 5 stars$6.97-4.1%$30.40+336.2%-58.1%$339.53M$40K-1.97120Positive NewsALTAltimmune2.7066 of 5 stars$3.71-1.9%$17.40+369.0%-53.8%$333.61M$20K-3.1450ALDXAldeyra Therapeutics2.3264 of 5 stars$5.70+2.5%$9.50+66.7%-10.6%$333.02MN/A-6.7110Positive NewsFHTXFoghorn Therapeutics2.763 of 5 stars$5.75-0.3%$10.67+85.5%-46.6%$326.18M$22.60M-4.83120Positive News Related Companies and Tools Related Companies Benitec Biopharma Competitors I-Mab Competitors Upexi Competitors Rocket Pharmaceuticals Competitors Abeona Therapeutics Competitors Canopy Growth Competitors 4D Molecular Therapeutics Competitors Altimmune Competitors Aldeyra Therapeutics Competitors Foghorn Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORMP) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORMP Stock Alerts